期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
通过原生质体技术提高泰乐菌素产生菌的产量 被引量:3
1
作者 李向红 周启 万中义 《应用与环境生物学报》 CAS CSCD 1996年第3期315-319,共5页
从泰乐菌素产生菌弗氏链霉菌028-3菌株出发,通过NTG多次诱变,获得一株泰乐菌素产量提高2倍以上的突变株H188.再以原生质体再生和原生质作诱变后再生的手段,经过连续两轮处理,获得两株突变株:A117和D85.在最... 从泰乐菌素产生菌弗氏链霉菌028-3菌株出发,通过NTG多次诱变,获得一株泰乐菌素产量提高2倍以上的突变株H188.再以原生质体再生和原生质作诱变后再生的手段,经过连续两轮处理,获得两株突变株:A117和D85.在最佳发酵培养基条件下,它们的泰乐菌素产量比H188分别提高6.5倍和5.5倍以上. 展开更多
关键词 弗氏链霉菌 泰乐菌素 原生质体再生 抗菌素学
下载PDF
多粘菌素-B的溶液构象研究 被引量:2
2
作者 袁越 刘修才 顾孝诚 《生物物理学报》 CAS CSCD 北大核心 1997年第3期380-386,共7页
利用核磁共振技术对多粘菌素-B在溶液中的构象进行测定。多粘菌素-B的全部质子信号及3JHNα均得到归属和确认。大部分存在于环肽及侧链的分子间NOE得到归属。
关键词 抗菌素学 多粘菌素-B 核磁共振 结构
下载PDF
Re-evaluation of antitumor effects of combination chemotherapy with interferon-α and 5-fluorouracil for advanced hepatocellular carcinoma 被引量:2
3
作者 Munechika Enjoji Shusuke Morizono +4 位作者 Kazuhiro Kotoh Motoyuki Kohjima Yuzuru Miyagi Tsuyoshi Yoshimoto Makoto Nakamuta 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第36期5685-5687,共3页
AIM: To evaluate the efficacy of combination chemotherapy with interferon-α (IFNα) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC). METHODS: Twenty-eight HCC patients in ad... AIM: To evaluate the efficacy of combination chemotherapy with interferon-α (IFNα) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC). METHODS: Twenty-eight HCC patients in advanced stage were enrolled in the study. They were treated with IFNα/ 5-FU combination chemotherapy. One cycle of therapy lasted for 4 wk. IFNα (3×10^6 units) was subcutaneously injected thrice weekly on days 1, 3, and 5 for 3 wk, and 5-FU (500 mg/d) was administered via the proper hepatic artery for 5 consecutive days per week for 3 wk. No drugs were administered during the 4th wk. The effect of combination chemotherapy was evaluated in each patient alter every cycle based on the reduction of tumor volume. RESULTS: Alter the 1^st cycle of therapy, 16 patients showed a partial response (PR, 57.1%) but none showed a complete response (CR, 0%). At the end of therapy, the number of patients who showed a CR, PR, or no response (NR) was 1, 10, and 17, respectively. The response rate for therapy (CR+PR) was 21.5%. Biochemical tests before therapy were compared between responsive (CR+PR) and non-responsive (NR) patients, but no significant differences were found for any of the parameters examined, indicating that no reasonable predictors could be identified in our analysis. CONCLUSION: Attempts should be made to discriminate between responders and non-responders by evaluating tumor size alter the first cycle of IFNα/5-FU combination chemotherapy. For non-responders, therapy should not proceed to the next cycle, and instead, different combination of anticancer drugs should be explored. 2005 The WJG Press and Elsevier Inc. All rights reserved 展开更多
关键词 INTERFERON-Α 5-FLUOROURACIL Hepatocellular carcinoma CHEMOTHERAPY
下载PDF
Role of antibiotic therapy in bacterial disease:A mathematical study
4
作者 Priti Kumar Roy Yanhui Zhang +2 位作者 Priyanka Ghosh Joydeep Pals Fahad Al Basir 《International Journal of Biomathematics》 SCIE 2018年第3期131-154,共24页
Pathogenic bacteria in human system mature through the bin-synthesis of protective layer known as cell wall. This bacterial cell wall growth occurs in the presence of enzyme released by it. After maturation by the cel... Pathogenic bacteria in human system mature through the bin-synthesis of protective layer known as cell wall. This bacterial cell wall growth occurs in the presence of enzyme released by it. After maturation by the cell wall formation, pathogenic bacteria become harmful for human body as they are responsible for different diseases. Antibiotics or drugs are employed for curing bacterial diseases through the inhibition of this maturation process and it occurs by the binding progression of antibiotics with the released enzyme. But nowadays, drugs or antibiotics like β-lactum family (Amoxcillin) which are generally used for inhibition of bin-synthesis of cell wall become ineffective due to evolution of antibiotic resistance by the bacteria. Antibiotic resistance occurs when an antibiotic has lost its ability to effectively control or kill bacterial growth. As a result, the bacteria becomes "resistant" and continue to multiply for the generation of robust pathogenic bacteria in spite of drug administration. This is due to the release of another type of enzyme by the resistant bacteria which binds with the active antibiotic or drug making it ineffective. Hence, another type of drug (Clauvanic acid) is combined to resist the activity of drug hydrolyzing enzyme so that the initial drug can act effectively. Hence a combination of drug therapy is applied to cure the bacterial diseases successfully. We developed a mathematical model based on the bacterial enzyme and bacterial cell wall proliferation mechanism and showed how we can reduce the bacterial infection in the resistant cases with application of combination drugs (Amoxcillin and Clauvanic acid) to restore normal health. Based on the enzymatic activity and individual drug dynamics we studied the overall system under the single drug and combinational drug administra- tion through our formulated model analysis. We also demonstrated the different dosing time interval and dosing concentration to evaluate the optimized drug administration for arresting the cell wall formation completely. Sensitivity of the different kinetic rate constant also has been performed with subject to drug hydrolyzing enzyme. Our analytical and numerical studies also confirm the efficiency of the combinational drug treatment compared to single drug treatment being more effective in drug resistant cases providing recovery from bacterial disease. 展开更多
关键词 BACTERIA cell wall resistance enzyme inhibition modeling impulsive drug dosing.
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部